Conference abstract · 29 Aug 2020
ArticlePublished 2015
Mitochondrial DNA Mutation in Microglia Can Be Treated by SCNT Cloning and Not by Reprogramming of Olfactory Ensheathing Cells in the Multiple Sclerosis Treatment
Abstract
Select any words in the title or abstract, or press this and choose a sentence.
Background: Multiple sclerosis (MS) is a demyelinating chronic inflammatory neurological disease of the central nervous system (CNS), characterized by activation of microglia. Mitochondrial mutations (mtDNA.mutat) and dysfunctions inmicroglial cells are thought to centrally contribute to the damaging effects of neuroinflammation seen in MS. Objective: The somatic nuclear transfer (SCNT) technology offers a more practical mode of therapy in MS, This method would attempt to dilute and/or progressively replace the (mtDNA.mutat) and activated microglia with cloned olfactory ensheathing cells (OEC) with remyelinating and scavenging properties which would attempt to limit the progression of MS. Proposed Methods: Applying SCNT-derived embryonic stem (ES) cells based therapy by cloning olfactory ensheathing cells (OEC), engineered with an autologous nuclear component of the recipient OEC with a healthy donor oocyte. The inner cell mass of the subsequently developed blastocyst would be the source to generate the microglia. The novel proposed transcribrial route device offers a painless mode of cell transplantation to the brain. Expected Results: This mode of generating SCNT cloned glia and its transplantation to the brain is expected to replace the (mtDNA.mutat) and activated microglia of the patients with MS and use the regenerative and remyelinating and properties of the OEC’s, as has been seen in recent clinical trials in paraplegic patients with spinal cord injuries. Conclusion: The use of SCNT in contrast to the reprogramming adult somatic cell is expected to develop isogenic ES cell-based therapies for the prevention and treatment of MS associated with mtDNA mutations that may open a new avenue of designer’s targeted cell therapy unique for the patients with MS. The proposed “transcribrial device” to access the brain can be an advantageous route of delivery of cloned cells to the brain.
Subjects
Neuroscience & NeurologyAsk about this article
Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.
Similar by topic
Conference abstract · 2018
Interactions of mitochondrial matrix proteins 17β-hydroxysteroid dehydrogenase type 10 and cyclophilin D in people with Alzheimer disease and multiple sclerosis
Conference abstract · 2018
Laboratory assessment of mitochondrial dysfunction in patients with multiple sclerosis
Conference abstract · 2022
Sarcotubular Myopathy Due to Novel TRIM32 Mutation in Association with Multiple Sclerosis
Article · 5 Apr 2025
Neuropathogenesis and Neurological Effects of SARS-Cov-2 on Glial Cells and Its Potential Progression to Multiple Sclerosis
More from this journal
The newest in Journal of Multiple Sclerosis.
Article · 7 Apr 2026
A Link between Smoking and Age at Onset in Multiple Sclerosis
Article · 12 Feb 2026
Demyelination: Understanding the Disruption of Nerve Function
Article · 12 Feb 2026
Brain Tumors: Insights into Diagnosis, Management, and Future Perspectives
Conferences in this field
Upcoming conferences in this field.
Follow
New articles from what you follow go into your email digest, once you agree to alert emails.
- JournalJournal of Multiple Sclerosis
- SubjectNeuroscience & Neurology
- BylineArticles whose byline prints “Abdul Mannan Baig”

